{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:37:48Z","timestamp":1792712268090,"version":"4.5.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Basic Res Cardiol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00395-022-00934-7","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T16:03:12Z","timestamp":1652803392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia\/reperfusion injury: a class or a drug effect?"],"prefix":"10.1007","volume":"117","author":[{"given":"Panagiota Efstathia","family":"Nikolaou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Mylonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manousos","family":"Makridakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Makrecka-Kuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Iliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelios","family":"Zerikiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Efentakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Kampoukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kostomitsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinis","family":"Vilskersts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignatios","family":"Ikonomidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaia","family":"Lambadiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coert J.","family":"Zuurbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Latosinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Vlahou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios K.","family":"Iliodromitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1504-9942","authenticated-orcid":false,"given":"Ioanna","family":"Andreadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"934_CR1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.2337\/db17-0100","volume":"66","author":"H Al-Jobori","year":"2017","unstructured":"Al-Jobori H, Daniele G, Cersosimo E, Triplitt C, Mehta R, Norton L, DeFronzo RA, Abdul-Ghani M (2017) Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes. Diabetes 66:1999\u20132006. https:\/\/doi.org\/10.2337\/db17-0100","journal-title":"Diabetes"},{"key":"934_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/fcp.12548","volume":"34","author":"EF Amin","year":"2020","unstructured":"Amin EF, Rifaai RA, Abdel-Latif RG (2020) Empagliflozin attenuates transient cerebral ischemia\/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway. Fundam Clin Pharmacol 34:548\u2013558. https:\/\/doi.org\/10.1111\/fcp.12548","journal-title":"Fundam Clin Pharmacol"},{"key":"934_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165770","author":"I Andreadou","year":"2020","unstructured":"Andreadou I, Bell RM, B\u00f8tker HE, Zuurbier CJ (2020) SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Biochim Biophys Acta Mol Basis Dis. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165770","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"934_CR4","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/cvr\/cvz050","volume":"115","author":"I Andreadou","year":"2019","unstructured":"Andreadou I, Cabrera-Fuentes HA, Devaux Y, Frangogiannis NG, Frantz S, Guzik T, Liehn EA, Gomes CPC, Schulz R, Hausenloy DJ (2019) Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovasc Res 115:1117\u20131130. https:\/\/doi.org\/10.1093\/cvr\/cvz050","journal-title":"Cardiovasc Res"},{"key":"934_CR5","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","volume":"8","author":"I Andreadou","year":"2017","unstructured":"Andreadou I, Efentakis P, Balafas E, Togliatto G, Davos CH, Varela A, Dimitriou CA, Nikolaou P-E, Maratou E, Lambadiari V, Ikonomidis I, Kostomitsopoulos N, Brizzi MF, Dimitriadis G, Iliodromitis EK (2017) Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol 8:1077. https:\/\/doi.org\/10.3389\/fphys.2017.01077","journal-title":"Front Physiol"},{"key":"934_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1021\/acschemneuro.0c00722","volume":"12","author":"HH Arab","year":"2021","unstructured":"Arab HH, Safar MM, Shahin NN (2021) Targeting ROS-Dependent AKT\/GSK-3\u03b2\/NF-\u03baB and DJ-1\/Nrf2 pathways by dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced Parkinson\u2019s disease rat model. ACS Chem Neurosci 12:689\u2013703. https:\/\/doi.org\/10.1021\/acschemneuro.0c00722","journal-title":"ACS Chem Neurosci"},{"key":"934_CR7","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1002\/ijc.24748","volume":"125","author":"D Bai","year":"2009","unstructured":"Bai D, Ueno L, Vogt PK (2009) Akt-mediated regulation of NF\u03baB and the essentialness of NF\u03baB for the oncogenicity of PI3K and Akt. Int J Cancer 125:2863\u20132870. https:\/\/doi.org\/10.1002\/ijc.24748","journal-title":"Int J Cancer"},{"key":"934_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00395-019-0733-2","volume":"114","author":"HE Baker","year":"2019","unstructured":"Baker HE, Kiel AM, Luebbe ST, Simon BR, Earl CC, Regmi A, Roell WC, Mather KJ, Tune JD, Goodwill AG (2019) Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization. Basic Res Cardiol 114:25. https:\/\/doi.org\/10.1007\/s00395-019-0733-2","journal-title":"Basic Res Cardiol"},{"key":"934_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/cvr\/cvx149","volume":"114","author":"E Bertero","year":"2018","unstructured":"Bertero E, Prates Roma L, Ameri P, Maack C (2018) Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res 114:12\u201318. https:\/\/doi.org\/10.1093\/cvr\/cvx149","journal-title":"Cardiovasc Res"},{"key":"934_CR10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00395-010-0124-1","volume":"105","author":"K Boengler","year":"2010","unstructured":"Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R (2010) Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia\/reperfusion. Basic Res Cardiol 105:771\u2013785. https:\/\/doi.org\/10.1007\/s00395-010-0124-1","journal-title":"Basic Res Cardiol"},{"key":"934_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00395-018-0696-8","volume":"113","author":"HE B\u00f8tker","year":"2018","unstructured":"B\u00f8tker HE, Hausenloy D, Andreadou I, Antonucci S, Boengler K, Davidson SM, Deshwal S, Devaux Y, Di Lisa F, Di Sante M, Efentakis P, Femmin\u00f2 S, Garc\u00eda-Dorado D, Giricz Z, Ibanez B, Iliodromitis E, Kaludercic N, Kleinbongard P, Neuh\u00e4user M, Ovize M, Pagliaro P, Rahbek-Schmidt M, Ruiz-Meana M, Schl\u00fcter K-D, Schulz R, Skyschally A, Wilder C, Yellon DM, Ferdinandy P, Heusch G (2018) Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol 113:39. https:\/\/doi.org\/10.1007\/s00395-018-0696-8","journal-title":"Basic Res Cardiol"},{"key":"934_CR12","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383:1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"key":"934_CR13","doi-asserted-by":"publisher","first-page":"W305","DOI":"10.1093\/nar\/gkp427","volume":"37","author":"J Chen","year":"2009","unstructured":"Chen J, Bardes EE, Aronow BJ, Jegga AG (2009) ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 37:W305\u2013W311. https:\/\/doi.org\/10.1093\/nar\/gkp427","journal-title":"Nucleic Acids Res"},{"key":"934_CR14","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.1038\/onc.2009.49","volume":"27","author":"G Chinnadurai","year":"2008","unstructured":"Chinnadurai G, Vijayalingam S, Gibson SB (2008) BNIP3 subfamily BH3-only proteins: mitochondrial stress sensors in normal and pathological functions. Oncogene 27:S114\u2013S127. https:\/\/doi.org\/10.1038\/onc.2009.49","journal-title":"Oncogene"},{"key":"934_CR15","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2147\/DDDT.S114932","volume":"11","author":"F Cinti","year":"2017","unstructured":"Cinti F, Moffa S, Impronta F, Cefalo CM, Sun VA, Sorice GP, Mezza T, Giaccari A (2017) Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther 11:2905\u20132919. https:\/\/doi.org\/10.2147\/DDDT.S114932","journal-title":"Drug Des Devel Ther"},{"key":"934_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00395-021-00898-0","volume":"116","author":"S Comit\u00e0","year":"2021","unstructured":"Comit\u00e0 S, Femmino S, Thairi C, Alloatti G, Boengler K, Pagliaro P, Penna C (2021) Regulation of STAT3 and its role in cardioprotection by conditioning: focus on non-genomic roles targeting mitochondrial function. Basic Res Cardiol 116:56. https:\/\/doi.org\/10.1007\/s00395-021-00898-0","journal-title":"Basic Res Cardiol"},{"key":"934_CR17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M (2020) SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 17:761\u2013772. https:\/\/doi.org\/10.1038\/s41569-020-0406-8","journal-title":"Nat Rev Cardiol"},{"key":"934_CR18","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.yjmcc.2012.09.007","volume":"53","author":"A Das","year":"2012","unstructured":"Das A, Salloum FN, Durrant D, Ockaili R, Kukreja RC (2012) Rapamycin protects against myocardial ischemia-reperfusion injury through JAK2-STAT3 signaling pathway. J Mol Cell Cardiol 53:858\u2013869. https:\/\/doi.org\/10.1016\/j.yjmcc.2012.09.007","journal-title":"J Mol Cell Cardiol"},{"key":"934_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-7831-1_3","volume":"1782","author":"C Doerrier","year":"2018","unstructured":"Doerrier C, Garcia-Souza LF, Krumschnabel G, Wohlfarter Y, M\u00e9sz\u00e1ros AT, Gnaiger E (2018) High-resolution fluorespirometry and OXPHOS protocols for human cells, permeabilized fibers from small biopsies of muscle, and isolated mitochondria. Methods Mol Biol 1782:31\u201370. https:\/\/doi.org\/10.1007\/978-1-4939-7831-1_3","journal-title":"Methods Mol Biol"},{"key":"934_CR20","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.numecd.2017.08.005","volume":"27","author":"P Efentakis","year":"2017","unstructured":"Efentakis P, Rizakou A, Christodoulou E, Chatzianastasiou A, L\u00f3pez MG, Le\u00f3n R, Balafas E, Kadoglou NPE, Tseti I, Skaltsa H, Kostomitsopoulos N, Iliodromitis EK, Valsami G, Andreadou I (2017) Saffron (Crocus sativus) intake provides nutritional preconditioning against myocardial ischemia\u2013reperfusion injury in Wild Type and ApoE(\u2212\/\u2212) mice: Involvement of Nrf2 activation. Nutr Metab Cardiovasc Dis 27:919\u2013929. https:\/\/doi.org\/10.1016\/j.numecd.2017.08.005","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"934_CR21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-013-0064-9","volume":"73","author":"S Elkinson","year":"2013","unstructured":"Elkinson S, Scott LJ (2013) Canagliflozin: first global approval. Drugs 73:979\u2013988. https:\/\/doi.org\/10.1007\/s40265-013-0064-9","journal-title":"Drugs"},{"key":"934_CR22","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00395-008-0728-x","volume":"103","author":"BN Fuglesteg","year":"2008","unstructured":"Fuglesteg BN, Suleman N, Tiron C, Kanhema T, Lacerda L, Andreasen TV, Sack MN, Jonassen AK, Mj\u00f8s OD, Opie LH, Lecour S (2008) Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion. Basic Res Cardiol 103:444\u2013453. https:\/\/doi.org\/10.1007\/s00395-008-0728-x","journal-title":"Basic Res Cardiol"},{"key":"934_CR23","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","volume":"14","author":"A Garcia-Ropero","year":"2018","unstructured":"Garcia-Ropero A, Badimon JJ, Santos-Gallego CG (2018) The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol 14:1287\u20131302. https:\/\/doi.org\/10.1080\/17425255.2018.1551877","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"934_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096567","volume":"9","author":"N Gedik","year":"2014","unstructured":"Gedik N, Thielmann M, Kottenberg E, Peters J, Jakob H, Heusch G, Kleinbongard P (2014) No evidence for activated autophagy in left ventricular myocardium at early reperfusion with protection by remote ischemic preconditioning in patients undergoing coronary artery bypass grafting. PLoS ONE 9:e96567. https:\/\/doi.org\/10.1371\/journal.pone.0096567","journal-title":"PLoS ONE"},{"key":"934_CR25","doi-asserted-by":"publisher","first-page":"H478","DOI":"10.1152\/ajpheart.00749.2016","volume":"312","author":"S Gent","year":"2017","unstructured":"Gent S, Skyschally A, Kleinbongard P, Heusch G (2017) Ischemic preconditioning in pigs: a causal role for signal transducer and activator of transcription 3. Am J Physiol Heart Circ Physiol 312:H478\u2013H484. https:\/\/doi.org\/10.1152\/ajpheart.00749.2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"934_CR26","doi-asserted-by":"publisher","first-page":"6944","DOI":"10.3390\/ijms22136944","volume":"22","author":"M Ghomlaghi","year":"2021","unstructured":"Ghomlaghi M, Hart A, Hoang N, Shin S, Nguyen LK (2021) Feedback, crosstalk and competition: ingredients for emergent non-linear behaviour in the PI3K\/mTOR Signalling Network. Int J Mol Sci 22:6944. https:\/\/doi.org\/10.3390\/ijms22136944","journal-title":"Int J Mol Sci"},{"key":"934_CR27","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jacc.2004.06.071","volume":"44","author":"RJ Gibbons","year":"2004","unstructured":"Gibbons RJ, Valeti US, Araoz PA, Jaffe AS (2004) The quantification of infarct size. J Am Coll Cardiol 44:1533\u20131542. https:\/\/doi.org\/10.1016\/j.jacc.2004.06.071","journal-title":"J Am Coll Cardiol"},{"key":"934_CR28","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1161\/CIRCRESAHA.110.226928","volume":"108","author":"JW Gordon","year":"2011","unstructured":"Gordon JW, Shaw JA, Kirshenbaum LA (2011) Multiple facets of NF-\u03baB in the heart. Circ Res 108:1122\u20131132. https:\/\/doi.org\/10.1161\/CIRCRESAHA.110.226928","journal-title":"Circ Res"},{"key":"934_CR29","volume-title":"Assay guidance manual","author":"J Haas","year":"2004","unstructured":"Haas J, Manro J, Shannon H, Anderson W, Brozinick J, Chakravartty A, Chambers M, Du J, Eastwood B, Heuer J, Iturria S, Iversen P, Johnson D, Johnson K, O\u2019Neill M, Qian H-R, Sindelar D, Svensson K (2004) In vivo assay guidelines. In: Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin CP, Baell J, Chung TDY, Coussens NP, Dahlin JL, Devanarayan V, Foley TL, Glicksman M, Hall MD, Haas JV, Hoare SRJ, Inglese J, Iversen PW, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Sittampalam GS, Tarselli M, Trask OJ, Wang Y, Weidner JR, Wildey MJ, Wilson K, Xia M, Xu X (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda"},{"key":"934_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/cvr\/cvp062","volume":"83","author":"DJ Hausenloy","year":"2009","unstructured":"Hausenloy DJ, Yellon DM (2009) Cardioprotective growth factors. Cardiovasc Res 83:179\u2013194. https:\/\/doi.org\/10.1093\/cvr\/cvp062","journal-title":"Cardiovasc Res"},{"key":"934_CR31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1161\/CIRCRESAHA.116.305348","volume":"116","author":"G Heusch","year":"2015","unstructured":"Heusch G (2015) Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res 116:674\u2013699. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.305348","journal-title":"Circ Res"},{"key":"934_CR32","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41569-020-0403-y","volume":"17","author":"G Heusch","year":"2020","unstructured":"Heusch G (2020) Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol 17:773\u2013789. https:\/\/doi.org\/10.1038\/s41569-020-0403-y","journal-title":"Nat Rev Cardiol"},{"key":"934_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1161\/CIRCRESAHA.111.259556","volume":"110","author":"G Heusch","year":"2012","unstructured":"Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, Thielmann M (2012) STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: short communication. Circ Res 110:111\u2013115. https:\/\/doi.org\/10.1161\/CIRCRESAHA.111.259556","journal-title":"Circ Res"},{"key":"934_CR34","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.12278","volume":"3","author":"SL House","year":"2015","unstructured":"House SL, Wang J, Castro AM, Weinheimer C, Kovacs A, Ornitz DM (2015) Fibroblast growth factor 2 is an essential cardioprotective factor in a closed-chest model of cardiac ischemia-reperfusion injury. Physiol Rep 3:e12278. https:\/\/doi.org\/10.14814\/phy2.12278","journal-title":"Physiol Rep"},{"key":"934_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fcell.2016.00110","volume":"4","author":"N Itoh","year":"2016","unstructured":"Itoh N, Ohta H, Nakayama Y, Konishi M (2016) Roles of FGF signals in heart development, health, and disease. Front Cell Dev Biol 4:110. https:\/\/doi.org\/10.3389\/fcell.2016.00110","journal-title":"Front Cell Dev Biol"},{"key":"934_CR36","doi-asserted-by":"publisher","first-page":"D498","DOI":"10.1093\/nar\/gkz1031","volume":"48","author":"B Jassal","year":"2020","unstructured":"Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J, Gillespie M, Haw R, Loney F, May B, Milacic M, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Weiser J, Wu G, Stein L, Hermjakob H, D\u2019Eustachio P (2020) The reactome pathway knowledgebase. Nucleic Acids Res 48:D498\u2013D503. https:\/\/doi.org\/10.1093\/nar\/gkz1031","journal-title":"Nucleic Acids Res"},{"key":"934_CR37","doi-asserted-by":"publisher","first-page":"W96","DOI":"10.1093\/nar\/gkq418","volume":"38","author":"V Kaimal","year":"2010","unstructured":"Kaimal V, Bardes EE, Tabar SC, Jegga AG, Aronow BJ (2010) ToppCluster: a multiple gene list feature analyzer for comparative enrichment clustering and network-based dissection of biological systems. Nucleic Acids Res 38:W96\u2013W102. https:\/\/doi.org\/10.1093\/nar\/gkq418","journal-title":"Nucleic Acids Res"},{"key":"934_CR38","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cjca.2019.08.033","volume":"36","author":"S Kang","year":"2020","unstructured":"Kang S, Verma S, Hassanabad AF, Teng G, Belke DD, Dundas JA, Guzzardi DG, Svystonyuk DA, Pattar SS, Park DSJ, Turnbull JD, Duff HJ, Tibbles LA, Cunnington RH, Dyck JRB, Fedak PWM (2020) Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME Results. Can J Cardiol 36:543\u2013553. https:\/\/doi.org\/10.1016\/j.cjca.2019.08.033","journal-title":"Can J Cardiol"},{"key":"934_CR39","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10741-007-9027-0","volume":"12","author":"E Kardami","year":"2007","unstructured":"Kardami E, Detillieux K, Ma X, Jiang Z, Santiago J-J, Jimenez SK, Cattini PA (2007) Fibroblast growth factor-2 and cardioprotection. Heart Fail Rev 12:267\u2013277. https:\/\/doi.org\/10.1007\/s10741-007-9027-0","journal-title":"Heart Fail Rev"},{"key":"934_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00395-017-0660-z","volume":"113","author":"P Kleinbongard","year":"2018","unstructured":"Kleinbongard P, Skyschally A, Gent S, Pesch M, Heusch G (2018) STAT3 as a common signal of ischemic conditioning: a lesson on \u201crigor and reproducibility\u201d in preclinical studies on cardioprotection. Basic Res Cardiol 113:3. https:\/\/doi.org\/10.1007\/s00395-017-0660-z","journal-title":"Basic Res Cardiol"},{"key":"934_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12933-018-0745-5","volume":"17","author":"S Lahnwong","year":"2018","unstructured":"Lahnwong S, Chattipakorn SC, Chattipakorn N (2018) Potential mechanisms responsible for cardioprotective effects of sodium\u2013glucose co-transporter 2 inhibitors. Cardiovasc Diabetol 17:101. https:\/\/doi.org\/10.1186\/s12933-018-0745-5","journal-title":"Cardiovasc Diabetol"},{"key":"934_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","volume":"19","author":"S Lahnwong","year":"2020","unstructured":"Lahnwong S, Palee S, Apaijai N, Sriwichaiin S, Kerdphoo S, Jaiwongkam T, Chattipakorn SC, Chattipakorn N (2020) Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury. Cardiovasc Diabetol 19:91. https:\/\/doi.org\/10.1186\/s12933-020-01066-9","journal-title":"Cardiovasc Diabetol"},{"key":"934_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1046\/j.1365-2613.1999.00114.x","volume":"80","author":"DS Latchman","year":"1999","unstructured":"Latchman DS (1999) Cardiotrophin-1 (CT-1): a novel hypertrophic and cardioprotective agent. Int J Exp Pathol 80:189\u2013196. https:\/\/doi.org\/10.1046\/j.1365-2613.1999.00114.x","journal-title":"Int J Exp Pathol"},{"key":"934_CR44","doi-asserted-by":"publisher","first-page":"25619","DOI":"10.1038\/srep25619","volume":"6","author":"A Latosinska","year":"2016","unstructured":"Latosinska A, Makridakis M, Frantzi M, Borr\u00e0s DM, Janssen B, Mullen W, Zoidakis J, Merseburger AS, Jankowski V, Mischak H, Vlahou A (2016) Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of \u2013omics findings. Sci Rep 6:25619. https:\/\/doi.org\/10.1038\/srep25619","journal-title":"Sci Rep"},{"key":"934_CR45","doi-asserted-by":"publisher","first-page":"69435","DOI":"10.18632\/oncotarget.17279","volume":"8","author":"A Latosinska","year":"2017","unstructured":"Latosinska A, Mokou M, Makridakis M, Mullen W, Zoidakis J, Lygirou V, Frantzi M, Katafigiotis I, Stravodimos K, Hupe MC, Dobrzynski M, Kolch W, Merseburger AS, Mischak H, Roubelakis MG, Vlahou A (2017) Proteomics analysis of bladder cancer invasion: targeting EIF3D for therapeutic intervention. Oncotarget 8:69435\u201369455. https:\/\/doi.org\/10.18632\/oncotarget.17279","journal-title":"Oncotarget"},{"key":"934_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00395-021-00893-5","volume":"116","author":"S Lecour","year":"2021","unstructured":"Lecour S, Andreadou I, B\u00f8tker HE, Davidson SM, Heusch G, Ruiz-Meana M, Schulz R, Zuurbier CJ, Ferdinandy P, Hausenloy DJ, the European Union-CARDIOPROTECTION COST ACTION CA16225 (2021) IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. Basic Res Cardiol 116:52. https:\/\/doi.org\/10.1007\/s00395-021-00893-5","journal-title":"Basic Res Cardiol"},{"key":"934_CR47","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9836302","volume":"2019","author":"S Lei","year":"2019","unstructured":"Lei S, Su W, Xia Z-Y, Wang Y, Zhou L, Qiao S, Zhao B, Xia Z, Irwin MG (2019) Hyperglycemia-induced oxidative stress abrogates remifentanil preconditioning-mediated cardioprotection in diabetic rats by impairing caveolin-3-modulated PI3K\/Akt and JAK2\/STAT3 Signaling. Oxid Med Cell Long 2019:e9836302. https:\/\/doi.org\/10.1155\/2019\/9836302","journal-title":"Oxid Med Cell Long"},{"key":"934_CR48","doi-asserted-by":"publisher","first-page":"R972","DOI":"10.1152\/ajpregu.00227.2019","volume":"318","author":"LC Li Puma","year":"2020","unstructured":"Li Puma LC, Hedges M, Heckman JM, Mathias AB, Engstrom MR, Brown AB, Chicco AJ (2020) Experimental oxygen concentration influences rates of mitochondrial hydrogen peroxide release from cardiac and skeletal muscle preparations. Am J Physiol Regul Integr Comp Physiol 318:R972\u2013R980. https:\/\/doi.org\/10.1152\/ajpregu.00227.2019","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"934_CR49","doi-asserted-by":"publisher","first-page":"W199","DOI":"10.1093\/nar\/gkz401","volume":"47","author":"Y Liao","year":"2019","unstructured":"Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B (2019) WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res 47:W199\u2013W205. https:\/\/doi.org\/10.1093\/nar\/gkz401","journal-title":"Nucleic Acids Res"},{"key":"934_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12967-018-1476-9","volume":"16","author":"V Lygirou","year":"2018","unstructured":"Lygirou V, Latosinska A, Makridakis M, Mullen W, Delles C, Schanstra JP, Zoidakis J, Pieske B, Mischak H, Vlahou A (2018) Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease. J Transl Med 16:104. https:\/\/doi.org\/10.1186\/s12967-018-1476-9","journal-title":"J Transl Med"},{"key":"934_CR51","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s10557-020-06989-9","volume":"34","author":"M Makrecka-Kuka","year":"2020","unstructured":"Makrecka-Kuka M, Korzh S, Videja M, Vilks K, Cirule H, Kuka J, Dambrova M, Liepinsh E (2020) Empagliflozin protects cardiac mitochondrial fatty acid metabolism in a mouse model of diet-induced lipid overload. Cardiovasc Drugs Ther 34:791\u2013797. https:\/\/doi.org\/10.1007\/s10557-020-06989-9","journal-title":"Cardiovasc Drugs Ther"},{"key":"934_CR52","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3390\/biom5031319","volume":"5","author":"M Makrecka-Kuka","year":"2015","unstructured":"Makrecka-Kuka M, Krumschnabel G, Gnaiger E (2015) High-resolution respirometry for simultaneous measurement of oxygen and hydrogen peroxide fluxes in permeabilized cells, tissue homogenate and isolated mitochondria. Biomolecules 5:1319\u20131338. https:\/\/doi.org\/10.3390\/biom5031319","journal-title":"Biomolecules"},{"key":"934_CR53","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40265-018-0878-6","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A (2018) Ertugliflozin: first global approval. Drugs 78:513\u2013519. https:\/\/doi.org\/10.1007\/s40265-018-0878-6","journal-title":"Drugs"},{"key":"934_CR54","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s40265-019-01146-5","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Keam SJ (2019) Sotagliflozin: first global approval. Drugs 79:1023\u20131029. https:\/\/doi.org\/10.1007\/s40265-019-01146-5","journal-title":"Drugs"},{"key":"934_CR55","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1161\/HYPERTENSIONAHA.118.11874","volume":"73","author":"E Mart\u00ednez-Mart\u00ednez","year":"2019","unstructured":"Mart\u00ednez-Mart\u00ednez E, Brugnolaro C, Ibarrola J, Ravassa S, Buonafine M, L\u00f3pez B, Fern\u00e1ndez-Celis A, Querejeta R, Santamaria E, Fern\u00e1ndez-Irigoyen J, R\u00e1bago G, Moreno MU, Jaisser F, D\u00edez J, Gonz\u00e1lez A, L\u00f3pez-Andr\u00e9s N (2019) CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) axis in cardiac fibrosis and inflammation. Hypertension 73:602\u2013611. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11874","journal-title":"Hypertension"},{"key":"934_CR56","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document Group (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"934_CR57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, B\u00f6hm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Duk\u00e1t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sj\u00f6strand M, Langkilde A-M, DAPA-HF Trial Committees and Investigators (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"934_CR58","doi-asserted-by":"publisher","first-page":"W566","DOI":"10.1093\/nar\/gkv468","volume":"43","author":"T Metsalu","year":"2015","unstructured":"Metsalu T, Vilo J (2015) ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res 43:W566\u2013W570. https:\/\/doi.org\/10.1093\/nar\/gkv468","journal-title":"Nucleic Acids Res"},{"key":"934_CR59","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2174\/1573399813666170816142351","volume":"14","author":"MG Minze","year":"2018","unstructured":"Minze MG, Will KJ, Terrell BT, Black RL, Irons BK (2018) Benefits of SGLT2 inhibitors beyond glycemic control\u2014a focus on metabolic, cardiovascular and renal outcomes. Curr Diabetes Rev 14:509\u2013517. https:\/\/doi.org\/10.2174\/1573399813666170816142351","journal-title":"Curr Diabetes Rev"},{"key":"934_CR60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ebiom.2019.02.040","volume":"41","author":"M Mokou","year":"2019","unstructured":"Mokou M, Klein J, Makridakis M, Bitsika V, Bascands J-L, Saulnier-Blache JS, Mullen W, Sacherer M, Zoidakis J, Pieske B, Mischak H, Roubelakis MG, Schanstra JP, Vlahou A (2019) Proteomics based identification of KDM5 histone demethylases associated with cardiovascular disease. EBioMedicine 41:91\u2013104. https:\/\/doi.org\/10.1016\/j.ebiom.2019.02.040","journal-title":"EBioMedicine"},{"key":"934_CR61","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.molcel.2021.01.033","volume":"81","author":"R Mukherjee","year":"2021","unstructured":"Mukherjee R, Vanaja KG, Boyer JA, Gadal S, Solomon H, Chandarlapaty S, Levchenko A, Rosen N (2021) Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Mol Cell 81:708-723.e5. https:\/\/doi.org\/10.1016\/j.molcel.2021.01.033","journal-title":"Mol Cell"},{"key":"934_CR62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7:27\u201331. https:\/\/doi.org\/10.4103\/0976-0105.177703","journal-title":"J Basic Clin Pharm"},{"key":"934_CR63","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"934_CR64","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/cvr\/cvz061","volume":"115","author":"P-E Nikolaou","year":"2019","unstructured":"Nikolaou P-E, Boengler K, Efentakis P, Vouvogiannopoulou K, Zoga A, Gaboriaud-Kolar N, Myrianthopoulos V, Alexakos P, Kostomitsopoulos N, Rerras I, Tsantili-Kakoulidou A, Skaltsounis AL, Papapetropoulos A, Iliodromitis EK, Schulz R, Andreadou I (2019) Investigating and re-evaluating the role of glycogen synthase kinase 3 beta kinase as a molecular target for cardioprotection by using novel pharmacological inhibitors. Cardiovasc Res 115:1228\u20131243. https:\/\/doi.org\/10.1093\/cvr\/cvz061","journal-title":"Cardiovasc Res"},{"key":"934_CR65","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1089\/ars.2019.7923","volume":"34","author":"PE Nikolaou","year":"2021","unstructured":"Nikolaou PE, Efentakis P, Abu Qourah F, Femmin\u00f2 S, Makridakis M, Kanaki Z, Varela A, Tsoumani M, Davos CH, Dimitriou CA, Tasouli A, Dimitriadis G, Kostomitsopoulos N, Zuurbier CJ, Vlahou A, Klinakis A, Brizzi MF, Iliodromitis EK, Andreadou I (2021) Chronic empagliflozin treatment reduces myocardial infarct size in nondiabetic mice through STAT-3-mediated protection on microvascular endothelial cells and reduction of oxidative stress. Antioxid Redox Signal 34:551\u2013571. https:\/\/doi.org\/10.1089\/ars.2019.7923","journal-title":"Antioxid Redox Signal"},{"key":"934_CR66","doi-asserted-by":"publisher","DOI":"10.4172\/2329-6607.1000210","author":"J Nr","year":"2017","unstructured":"Nr J, Tr L, Hjortbak MV, St\u00f8ttrup NB, B\u00f8tker HR (2017) Sodium glucose transporter 2 (SGLT2) inhibition does not protect the myocardium from acute ischemic reperfusion injury but modulates post- ischemic mitochondrial function. Cardiovasc Pharm Open Access. https:\/\/doi.org\/10.4172\/2329-6607.1000210","journal-title":"Cardiovasc Pharm Open Access"},{"key":"934_CR67","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, B\u00f6hm M, Choi D-J, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca H-P, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde M-F, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR-Reduced Trial Investigators, (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"934_CR68","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-1-4614-1222-9_10","volume":"729","author":"M Panneerselvam","year":"2012","unstructured":"Panneerselvam M, Patel HH, Roth DM (2012) Caveolins and heart diseases. Adv Exp Med Biol 729:145\u2013156. https:\/\/doi.org\/10.1007\/978-1-4614-1222-9_10","journal-title":"Adv Exp Med Biol"},{"key":"934_CR69","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu P-L, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial Investigators (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"934_CR70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-1-61779-382-0_3","volume":"810","author":"D Pesta","year":"2012","unstructured":"Pesta D, Gnaiger E (2012) High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods Mol Biol 810:25\u201358. https:\/\/doi.org\/10.1007\/978-1-61779-382-0_3","journal-title":"Methods Mol Biol"},{"key":"934_CR71","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.2165\/11209910-000000000-00000","volume":"72","author":"GL Plosker","year":"2012","unstructured":"Plosker GL (2012) Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 72:2289\u20132312. https:\/\/doi.org\/10.2165\/11209910-000000000-00000","journal-title":"Drugs"},{"key":"934_CR72","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1152\/ajpendo.00439.2012","volume":"304","author":"DR Powell","year":"2013","unstructured":"Powell DR, DaCosta CM, Gay J, Ding Z-M, Smith M, Greer J, Doree D, Jeter-Jones S, Mseeh F, Rodriguez LA, Harris A, Buhring L, Platt KA, Vogel P, Brommage R, Shadoan MK, Sands AT, Zambrowicz B (2013) Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 304:E117\u2013E130. https:\/\/doi.org\/10.1152\/ajpendo.00439.2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"934_CR73","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"T Rieg","year":"2014","unstructured":"Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, Vallon V (2014) Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306:F188-193. https:\/\/doi.org\/10.1152\/ajprenal.00518.2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"934_CR74","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.yexcr.2003.10.032","volume":"294","author":"H Sauer","year":"2004","unstructured":"Sauer H, Neukirchen W, Rahimi G, Gr\u00fcnheck F, Hescheler J, Wartenberg M (2004) Involvement of reactive oxygen species in cardiotrophin-1-induced proliferation of cardiomyocytes differentiated from murine embryonic stem cells. Exp Cell Res 294:313\u2013324. https:\/\/doi.org\/10.1016\/j.yexcr.2003.10.032","journal-title":"Exp Cell Res"},{"key":"934_CR75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ (2015) Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75:33\u201359. https:\/\/doi.org\/10.1007\/s40265-014-0337-y","journal-title":"Drugs"},{"key":"934_CR76","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.chembiol.2006.09.018","volume":"13","author":"J Schust","year":"2006","unstructured":"Schust J, Sperl B, Hollis A, Mayer TU, Berg T (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13:1235\u20131242. https:\/\/doi.org\/10.1016\/j.chembiol.2006.09.018","journal-title":"Chem Biol"},{"key":"934_CR77","doi-asserted-by":"publisher","first-page":"9544","DOI":"10.1038\/s41598-021-89149-9","volume":"11","author":"JM Seefeldt","year":"2021","unstructured":"Seefeldt JM, Lassen TR, Hjortbak MV, Jespersen NR, Kvist F, Hansen J, B\u00f8tker HE (2021) Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats. Sci Rep 11:9544. https:\/\/doi.org\/10.1038\/s41598-021-89149-9","journal-title":"Sci Rep"},{"key":"934_CR78","doi-asserted-by":"publisher","first-page":"H1039","DOI":"10.1152\/ajpheart.2001.280.3.H1039","volume":"280","author":"F Sheikh","year":"2001","unstructured":"Sheikh F, Sontag DP, Fandrich RR, Kardami E, Cattini PA (2001) Overexpression of FGF-2 increases cardiac myocyte viability after injury in isolated mouse hearts. Am J Physiol Heart Circ Physiol 280:H1039-1050. https:\/\/doi.org\/10.1152\/ajpheart.2001.280.3.H1039","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"934_CR79","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00125-019-05071-w","volume":"63","author":"J Shirakawa","year":"2020","unstructured":"Shirakawa J, Tajima K, Okuyama T, Kyohara M, Togashi Y, De Jesus DF, Basile G, Kin T, Shapiro AMJ, Kulkarni RN, Terauchi Y (2020) Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. Diabetologia 63:577\u2013587. https:\/\/doi.org\/10.1007\/s00125-019-05071-w","journal-title":"Diabetologia"},{"key":"934_CR80","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCRESAHA.117.306878","volume":"117","author":"A Skyschally","year":"2015","unstructured":"Skyschally A, Gent S, Amanakis G, Schulte C, Kleinbongard P, Heusch G (2015) Across-species transfer of protection by remote ischemic preconditioning with species-specific myocardial signal transduction by reperfusion injury salvage kinase and survival activating factor enhancement pathways. Circ Res 117:279\u2013288. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.306878","journal-title":"Circ Res"},{"key":"934_CR81","doi-asserted-by":"publisher","first-page":"H159","DOI":"10.1152\/ajpheart.00152.2018","volume":"315","author":"A Skyschally","year":"2018","unstructured":"Skyschally A, Kleinbongard P, Lieder H, Gedik N, Stoian L, Amanakis G, Elbers E, Heusch G (2018) Humoral transfer and intramyocardial signal transduction of protection by remote ischemic perconditioning in pigs, rats, and mice. Am J Physiol Heart Circ Physiol 315:H159\u2013H172. https:\/\/doi.org\/10.1152\/ajpheart.00152.2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"934_CR82","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/ijms23010437","volume":"23","author":"Y Song","year":"2021","unstructured":"Song Y, Huang C, Sin J, de Germano JF, Taylor DJR, Thakur R, Gottlieb RA, Mentzer RM, Andres AM (2021) Attenuation of adverse postinfarction left ventricular remodeling with empagliflozin enhances mitochondria-linked cellular energetics and mitochondrial biogenesis. Int J Mol Sci 23:437. https:\/\/doi.org\/10.3390\/ijms23010437","journal-title":"Int J Mol Sci"},{"key":"934_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32556","author":"R Stroggilos","year":"2019","unstructured":"Stroggilos R, Mokou M, Latosinska A, Makridakis M, Lygirou V, Mavrogeorgis E, Drekolias D, Frantzi M, Mullen W, Fragkoulis C, Stasinopoulos K, Papadopoulos G, Stathouros G, Lazaris AC, Makrythanasis P, Ntoumas K, Mischak H, Zoidakis J, Vlahou A (2019) Proteome-based classification of nonmuscle invasive bladder cancer. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.32556","journal-title":"Int J Cancer"},{"key":"934_CR84","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jphs.2016.02.003","volume":"130","author":"A Tahara","year":"2016","unstructured":"Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E (2016) Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci 130:159\u2013169. https:\/\/doi.org\/10.1016\/j.jphs.2016.02.003","journal-title":"J Pharmacol Sci"},{"key":"934_CR85","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3390\/ph14090871","volume":"14","author":"C Trejo-Solis","year":"2021","unstructured":"Trejo-Solis C, Escamilla-Ramirez A, Jimenez-Farfan D, Castillo-Rodriguez RA, Flores-Najera A, Cruz-Salgado A (2021) Crosstalk of the Wnt\/\u03b2-catenin signaling pathway in the induction of apoptosis on cancer cells. Pharmaceuticals 14:871. https:\/\/doi.org\/10.3390\/ph14090871","journal-title":"Pharmaceuticals"},{"key":"934_CR86","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.108.788331","volume":"118","author":"YM Tsutsumi","year":"2008","unstructured":"Tsutsumi YM, Horikawa YT, Jennings MM, Kidd MW, Niesman IR, Yokoyama U, Head BP, Hagiwara Y, Ishikawa Y, Miyanohara A, Patel PM, Insel PA, Patel HH, Roth DM (2008) Cardiac-specific overexpression of caveolin-3 induces endogenous cardiac protection by mimicking ischemic preconditioning. Circulation 118:1979\u20131988. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.788331","journal-title":"Circulation"},{"key":"934_CR87","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1161\/CIRCRESAHA.113.300765","volume":"113","author":"RS Vander Heide","year":"2013","unstructured":"Vander Heide RS, Steenbergen C (2013) Cardioprotection and myocardial reperfusion. Circ Res 113:464\u2013477. https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.300765","journal-title":"Circ Res"},{"key":"934_CR88","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 61:2108\u20132117. https:\/\/doi.org\/10.1007\/s00125-018-4670-7","journal-title":"Diabetologia"},{"key":"934_CR89","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13300-020-00951-6","volume":"12","author":"DM Williams","year":"2021","unstructured":"Williams DM, Nawaz A, Evans M (2021) Sodium-glucose co-transporter 2 (SGLT2) inhibitors: are they all the same? A Narrative Review of Cardiovascular Outcome Trials. Diabetes Ther 12:55\u201370. https:\/\/doi.org\/10.1007\/s13300-020-00951-6","journal-title":"Diabetes Ther"},{"key":"934_CR90","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1039\/b504418a","volume":"3","author":"P Wipf","year":"2005","unstructured":"Wipf P, Halter RJ (2005) Chemistry and biology of wortmannin. Org Biomol Chem 3:2053\u20132061. https:\/\/doi.org\/10.1039\/b504418a","journal-title":"Org Biomol Chem"},{"key":"934_CR91","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde A-M, Sabatine MS, DECLARE\u2013TIMI 58 Investigators (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"934_CR92","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2337\/dc20-1983","volume":"44","author":"P Wolf","year":"2020","unstructured":"Wolf P, Fellinger P, Pfleger L, Beiglb\u00f6ck H, Krumpolec P, Barbieri C, Gastaldelli A, Harreiter J, Metz M, Scherer T, Zeyda M, Baumgartner-Parzer S, Marculescu R, Trattnig S, Kautzky-Willer A, Kr\u0161\u0161\u00e1k M, Krebs M (2020) Gluconeogenesis, but not glycogenolysis, contributes to the increase in endogenous glucose production by SGLT-2 inhibition. Diabetes Care 44:541\u2013548. https:\/\/doi.org\/10.2337\/dc20-1983","journal-title":"Diabetes Care"},{"key":"934_CR93","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00395-016-0561-6","volume":"111","author":"Y Yang","year":"2016","unstructured":"Yang Y, Ma Z, Hu W, Wang D, Jiang S, Fan C, Di S, Liu D, Sun Y, Yi W (2016) Caveolin-1\/-3: therapeutic targets for myocardial ischemia\/reperfusion injury. Basic Res Cardiol 111:45. https:\/\/doi.org\/10.1007\/s00395-016-0561-6","journal-title":"Basic Res Cardiol"},{"key":"934_CR94","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40256-014-0089-9","volume":"14","author":"H Yao","year":"2014","unstructured":"Yao H, Han X, Han X (2014) The cardioprotection of the insulin-mediated PI3K\/Akt\/mTOR signaling pathway. Am J Cardiovasc Drugs 14:433\u2013442. https:\/\/doi.org\/10.1007\/s40256-014-0089-9","journal-title":"Am J Cardiovasc Drugs"},{"key":"934_CR95","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","volume":"32","author":"Y Ye","year":"2018","unstructured":"Ye Y, Jia X, Bajaj M, Birnbaum Y (2018) Dapagliflozin attenuates Na+\/H+ Exchanger-1 in Cardiofibroblasts via AMPK activation. Cardiovasc Drugs Ther 32:553\u2013558. https:\/\/doi.org\/10.1007\/s10557-018-6837-3","journal-title":"Cardiovasc Drugs Ther"},{"key":"934_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.768214","volume":"8","author":"Y-W Yu","year":"2022","unstructured":"Yu Y-W, Que J-Q, Liu S, Huang K-Y, Qian L, Weng Y-B, Rong F-N, Wang L, Zhou Y-Y, Xue Y-J, Ji K-T (2022) Sodium-glucose co-transporter-2 inhibitor of dapagliflozin attenuates myocardial ischemia\/reperfusion injury by limiting NLRP3 inflammasome activation and modulating autophagy. Front Cardiovasc Med 8:768214. https:\/\/doi.org\/10.3389\/fcvm.2021.768214","journal-title":"Front Cardiovasc Med"},{"key":"934_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1473","author":"SR Yurista","year":"2019","unstructured":"Yurista SR, Sillj\u00e9 HHW, Oberdorf-Maass SU, Schouten E-M, Pavez Giani MG, Hillebrands J-L, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD (2019) Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.1473","journal-title":"Eur J Heart Fail"},{"key":"934_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.592233","volume":"7","author":"H Zhang","year":"2020","unstructured":"Zhang H, Uthman L, Bakker D, Sari S, Chen S, Hollmann MW, Coronel R, Weber NC, Houten SM, van Weeghel M, Zuurbier CJ (2020) Empagliflozin decreases lactate generation in an NHE-1 dependent fashion and increases \u03b1-ketoglutarate synthesis from palmitate in type ii diabetic mouse hearts. Front Cardiovasc Med 7:592233. https:\/\/doi.org\/10.3389\/fcvm.2020.592233","journal-title":"Front Cardiovasc Med"},{"key":"934_CR99","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nprot.2017.147","volume":"13","author":"X Zhang","year":"2018","unstructured":"Zhang X, Smits AH, van Tilburg GB, Ovaa H, Huber W, Vermeulen M (2018) Proteome-wide identification of ubiquitin interactions using UbIA-MS. Nat Protoc 13:530\u2013550. https:\/\/doi.org\/10.1038\/nprot.2017.147","journal-title":"Nat Protoc"},{"key":"934_CR100","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/cvr\/cvr029","volume":"91","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Lv F, Jin L, Peng W, Song R, Ma J, Cao C-M, Xiao R-P (2011) MG53 participates in ischaemic postconditioning through the RISK signalling pathway. Cardiovasc Res 91:108\u2013115. https:\/\/doi.org\/10.1093\/cvr\/cvr029","journal-title":"Cardiovasc Res"},{"key":"934_CR101","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"H Zhou","year":"2018","unstructured":"Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J (2018) Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol 15:335\u2013346. https:\/\/doi.org\/10.1016\/j.redox.2017.12.019","journal-title":"Redox Biol"},{"key":"934_CR102","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J M 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J M"}],"container-title":["Basic Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-022-00934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00395-022-00934-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-022-00934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T07:08:24Z","timestamp":1675062504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00395-022-00934-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1007\/s00395-022-00934-7","relation":{},"ISSN":["0300-8428","1435-1803"],"issn-type":[{"value":"0300-8428","type":"print"},{"value":"1435-1803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"assertion":[{"value":"21 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"27"}}